Eli Lilly and Company (LLY)
Eli Lilly: Bearish Signals Loom Over Weight Loss Stock Ahead Of Q2 Earnings
Eli Lilly and Co LLY will be reporting its second-quarter earnings on Thursday. Wall Street expects $2.70 in EPS and $9.9 billion in revenues as the company reports before market hours.
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
Eli Lilly and Company LLY is expected to release earnings results for its second quarter, before the opening bell on Thursday, Aug. 8.
Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look
Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.
Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Will The Supply Shortage Weigh On Eli Lilly's Q2?
Eli Lilly stock (NYSE: LLY) will report its Q2 results on Thursday, August 8. The pharmaceutical giant is expected to garner $10 billion in sales and $2.70 in adjusted earnings per share, per the consensus estimates.
Prediction: This Will Be the Best Pharmaceutical Stock to Own Over the Next 10 Years
Eli Lilly is a leader in diabetes and obesity care through its medications Mounjaro and Zepbound. Now, it's also set to enter the $31 billion Alzheimer's market following FDA approval of donanemab.
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These value-oriented businesses are also faithful dividend payers. Eli Lilly has scored multiple wins in recent months, and this established pharmaceutical giant is looking increasingly attractive for a long-term investment.
Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Lilly, Novo Nordisk battle for weight-loss market lands at the pharmacy shelf
As Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is simple: which drug can my patients actually get at the pharmacy?
Should You Buy Eli Lilly Before Aug. 8?
Eli Lilly shares have soared more than 230% over the past three years. The company has generated major growth thanks to its weight loss drugs.
Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic
My initial bearish thesis about Eli Lilly stock did not age well, as the stock has performed well since February despite being substantially overvalued. However, the market appears to be comfortable with the overvaluation as long as the company continues to capitalize on strong demand momentum for its diabetes and obesity drugs. Apart from the strong momentum of its stellar products like Mounjaro and Zepbound, there are several additional developments that contribute to my optimism.
